| Document |
Document Title |
|
WO/2022/166761A1 |
The present invention relates to a thienopyrimidine derivative, in particular to a compound, as represented by formula I, or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containi...
|
|
WO/2022/162107A1 |
The present invention relates to a crystalline form of risdiplam and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline form of risdiplam of the present inventi...
|
|
WO/2022/165494A1 |
The present disclosure relates to free base and salt crystals of 2-(4-acetylbenzyl)-3-((4-fluorophenyl)amino)-5,7,7-trimethyl
-7,8-dihydro-2H-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)
-one, composition comprising the same and the meth...
|
|
WO/2022/161421A1 |
A biphenyl compound as shown in formula (I), a preparation method therefor and use thereof, and a pharmaceutical composition comprising the compound as an active ingredient. The compound is a novel small-molecule immunomodulator having e...
|
|
WO/2022/163041A1 |
Provided are: an indole-structure-selective reaction agent and an indole-structure-selective crosslinking agent which are capable of selectively modifying, under mild conditions, an indole structure of a molecule (e.g., tryptophan) conta...
|
|
WO/2022/156445A1 |
An organic compound, and an electronic component and an electronic device using same, the organic compound has a structure as shown in formula A, formula B, formula D or formula F, wherein Ar is selected from substituted or unsubstituted...
|
|
WO/2022/159976A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2022/156803A1 |
Use of a pyrido[1,2-a]pyrimidone analogue. Specifically disclosed is use of a compound I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating and/or preventing cancers in the digestive tract syste...
|
|
WO/2022/156793A1 |
Disclosed are a quinoxaline-based D-A-D near-infrared two-region fluorescent molecule, and a preparation method therefor and the use thereof. The quinoxaline-based D-A-D near-infrared two-region fluorescent molecule is selected from comp...
|
|
WO/2021/257828A9 |
Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras su...
|
|
WO/2022/152274A1 |
An FGFR inhibitor compound represented by formula (I): [formula (I)].
|
|
WO/2022/148354A1 |
The present invention belongs to the technical field of medicine, and specifically relates to a polycyclic DNA-PK inhibitor compound as represented by general formula (I), a pharmaceutically acceptable salt thereof or an isomer thereof; ...
|
|
WO/2022/148434A1 |
Provided are a class of pyridone multiple-membered ring derivatives and the use thereof. Specifically provided are a compound as represented by formula (VI) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/143856A1 |
Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation...
|
|
WO/2022/147302A1 |
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2022/143864A1 |
The compound as shown in formula (I) or a pharmaceutically acceptable salt or pharmaceutical composition thereof, and a preparation method therefor, and the use thereof as an MAT2A inhibitor. Ring A, ring Q, X, Y, X1, X2, L and R1 in for...
|
|
WO/2022/138812A1 |
Provided is a tetrahydro thienopyridine sulfonamide compound that has PARG inhibition activity and is useful as an active ingredient of: a pharmaceutical composition for cancer therapy; a pharmaceutical composition for increasing the eff...
|
|
WO/2022/135560A1 |
The disclosure provides novel substituted imidazo [1, 5-b] pyridazine compounds as represented in Formula I: wherein A, R 0, R 1, R 2 and R 3 are defined herein. The compounds of Formula I are kinase inhibitors, especially ATR kinase inh...
|
|
WO/2022/134074A1 |
An organic electroluminescent device, a display panel, a display device and a light-emitting device are provided, belonging to the technical field of display. The organic electroluminescent device comprises an anode, an electron blocking...
|
|
WO/2022/140661A1 |
The present disclosure provides therapeutic methods of treating a cancer patient with a vinca alkaloide N-oxide and an immune checkpoint inhibitor.
|
|
WO/2022/140472A1 |
The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteosome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also prov...
|
|
WO/2022/140390A1 |
The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to...
|
|
WO/2022/138833A1 |
The present invention provides a photoelectric conversion element which is reduced in the electric field intensity dependency of a photoelectric conversion efficiency. The present invention also provides an imaging element, an optical se...
|
|
WO/2022/140428A2 |
The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to...
|
|
WO/2022/135580A1 |
A crystal form of a pyridopyrrole compound, and a preparation method therefor and the use thereof.
|
|
WO/2022/136174A1 |
The invention relates to pharmaceutical compounds of formula (I) and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of cyclin-depen...
|
|
WO/2022/137174A1 |
The present invention relates to solid forms of 7-(5-chloro-2-(3-(5-cyano-6-((1-(3,3-difluorocyclobutyl)pipe
ridin-4-yl)(methyl)amino)-2-methyl-4-oxopyrido[3,4-d]pyrimid
in-3(4H)-yl)prop-1-yn-1-yl)phenyl)-N-(methylsulfonyl)thieno[
3,2-b]...
|
|
WO/2022/127024A1 |
Disclosed are a nitrogen-containing heterocyclic compound and an application thereof, the nitrogen-containing heterocyclic compound having the structure shown in general formula (1) and, when used in an OLED, particularly as the main mat...
|
|
WO/2022/133345A1 |
Compounds with KRAS G12C inhibitory activity are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation. Preferably the compounds fall within formula (I).
|
|
WO/2022/127755A1 |
Provided herein are casein kinase inhibitors, or pharmaceutically acceptable salts thereof. Corresponding compositions, methods of treatment, and intermediates are also provided.
|
|
WO/2022/133064A1 |
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions th...
|
|
WO/2022/121825A1 |
A triazolo pyrazine compound, wherein the triazolo pyrazine compound is a compound as represented by formula (I) as follows, or a stereoisomer, a geometrical isomer, a tautomer, a hydrate, a solvate, and a pharmaceutically acceptable sal...
|
|
WO/2022/125971A1 |
The present disclosure provides methods of treating cancer with combination therapies of a SHP2 inhibitor and a KRAS G12C inhibitor.
|
|
WO/2022/121618A1 |
The present application relates to a nitrogen-containing compound, and an electronic component and electronic apparatus using same. The organic compound has a structure represented by the following formula (I). The nitrogen-containing co...
|
|
WO/2022/118910A1 |
[Problem] The purpose of the present invention is to provide a compound that has a high refractive index with respect to the wavelength range of 450-750 nm in a capping layer, in order to improve the light extraction efficiency of an org...
|
|
WO/2022/120118A1 |
Novel small molecule proteolysis-targeting chimeras (PROTACs) are provided, along with methods for their use as RIPK1 kinase degraders. The small molecule PROTACs described herein are useful in treating and/or preventing RIPK1 kinase-rel...
|
|
WO/2022/117111A1 |
Disclosed are a salt of a pyrrolopyrimidine compound, a crystalline form thereof, and an application thereof. Specifically provided are a crystal form of the compound represented by the formula I, a salt thereof, and a hydrate of the sal...
|
|
WO/2022/110052A1 |
A nitrogen-containing heterocyclic 5-HT3 receptor modulator, a preparation method therefor and use thereof, relating to the field of medicinal chemistry. The nitrogen-containing heterocyclic 5-HT3 receptor modulator is a compound as repr...
|
|
WO/2022/113371A1 |
Provided is a drug used for the treatment or prevention of cerebral hemorrhage, the drug containing, as an active ingredient, the compound of formula (I), or a pharmaceutically acceptable salt, ester or solvate thereof.
|
|
WO/2022/111636A1 |
The present invention relates to a fused tricyclic compound, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a fused tricyclic compound represented by general formula ...
|
|
WO/2022/111729A1 |
Disclosed are a salt form used as a CDC7 inhibitor and a crystal form thereof, and specifically disclosed is a compound represented by formula (II), a crystal form thereof, a preparation method therefor, and an application thereof in the...
|
|
WO/2022/114065A1 |
Provided are: a material that provides high sensitivity and high resolution to a photoelectric conversion element for imaging; and a photoelectric conversion element for imaging, using said material. This material of a photoelectric conv...
|
|
WO/2022/109495A1 |
Provided herein are, inter alia, methods and compositions for linking RNA stem loops. The methods include linking a first RNA stem loop and a second RNA stem loop by way of a preQ1 linking compound.
|
|
WO/2022/105313A1 |
The present application relates to an organic compound, and an organic electroluminescent device and an electronic device using the same. The structure of the organic compound is as shown in formula I. When the organic compound of the pr...
|
|
WO/2022/105921A1 |
The present invention relates to a class of pyrimido-heterocyclic compounds, a preparation method therefor, and a use thereof. The compound is specifically a pyrimido-fused ring compound represented by general formula I, or a pharmaceuti...
|
|
WO/2022/105857A1 |
Provided are KRAS G12D inhibitors of formula (I), a composition containing the inhibitors, a prodrug thereof, a PROTAC compound thereof and the use thereof.
|
|
WO/2022/101171A1 |
The present invention relates to sulfurous compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices containing said compounds.
|
|
WO/2022/100727A1 |
The present invention provides a novel class of imidazothiazole compounds as ATX (Autotaxin) inhibitors, a pharmaceutical composition comprising the compound, and a use of the compound and the composition to treat a mammal suffering from...
|
|
WO/2022/104079A1 |
Provided are compounds of Formula (I'): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.
|
|
WO/2022/104348A1 |
This invention relates to compounds of Formula I that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventing or treat...
|
